Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

5 results
Display

A Phase II Study of Vinorelbine, Mitomycin C and Cisplatin Chemotherapy for Advanced Non-Small Cell Lung Cancer

Kwon MR, Jeong TY, Yuh YJ, Kim SR

  • KMID: 759617
  • Korean J Intern Med.
  • 2002 Dec;17(4):240-244.
BACKGROUND: This prospective phase II trial was performed to determine the efficacy and toxicity of mitomycin C, vinorelbine and cisplatin combination chemotherapy for patients with previously untreated stage IIIB...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Vortex Keratopathy in a Patient Receiving Vandetanib for Non-Small Cell Lung Cancer

Ahn J, Wee WR, Lee JH, Hyon JY

We report a case of vortex keratopathy in a patient treated with vandetanib for non-small cell lung cancer (NSCLC). A 44-year-old female who underwent two cycles of chemotherapy for NSCLC...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Less Intensive Combination of Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer Patients who Have Aged 60 Years or More and Has a Poor Performance Status

Min YJ, Ahn JJ, Noh YJ, Cha HJ, Suh JH, Jung JP, Park CR, Jeong AK, Park JH, Lee KM

  • KMID: 759697
  • Korean J Intern Med.
  • 2004 Jun;19(2):109-113.
BACKGROUND: The aim of this study was to evaluate the response, survival, and toxicities of a less intensive combination of paclitaxel and carboplatin, which is used in advanced non-small cell...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

Ko YH, Lee MA, Hong YS, Lee KS, Park HJ, Yoo IR, Kim YS, Kim YK, Jo KH, Wang YP, Lee KY, Kang JH

BACKGROUND: Second-line chemotherapy offers advanced non-small cell lung cancer (NSCLC) patients a small, but significant increase in survival. Docetaxel is usually administered as a 3-week schedule, yet there is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Molecularly Targeted Therapy Using Bevacizumab for Non-Small Cell Lung Cancer: a Pilot Study for the New CT Response Criteria

Lee HY, Lee KS, Hwang HS, Lee JW, Ahn MJ, Park K, Kim TS, Yi CA, Chung MJ

OBJECTIVE: We wanted to compare the efficacy of the new CT response evaluation criteria for predicting the tumor progression-free survival (PFS) with that of RECIST 1.1 in non-small cell lung...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr